| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Departments of 1 Academic Surgery and 2 Pathology, South Manchester University and 3 The Christie Hospital NHS Trust, Manchester, United Kingdom
Requests for reprints: Nigel J. Bundred, Department of Academic Surgery, Research and Education Building, 2nd Floor, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester, M23 9LT, United Kingdom. Phone: 44-161-291-5859; Fax: 44-161-291-5860; E-mail: bundredn{at}man.ac.uk.
The type 1 tyrosine kinase receptor HER2 (c-erbB2/neu) is associated with resistance to hormone therapy and poor survival in invasive breast cancer, whereas HER4 expression is associated with endocrine responsiveness. Patterns of tyrosine kinase receptor coexpression may aid prediction of recurrence risk after surgery for ductal carcinoma in situ (DCIS). Women who had undergone surgery for pure DCIS were studied. Out of 129 primary tumors, 39 had recurred and 90 had not recurred after 5 years of follow-up. Primary tumors were compared for HER2, HER3, and HER4, estrogen receptor, and Ki67 by immunohistochemistry. HER2 was expressed in 58%, HER3 in 49%, and HER4 in 63% of nonrecurrent DCIS, compared with HER2 expression in 82% (P = 0.008), HER3 expression in 71% (P = 0.04), and HER4 expression in 36% (P = 0.004) in DCIS that subsequently recurred. Dually expressing HER2/4 DCIS was more likely to be estrogen receptor positive than HER2-only-expressing DCIS (73% versus 53%; P = 0.05). HER2 expression was associated with a higher percentage and HER4 expression a significantly lower percentage of proliferating DCIS cells (median, 13.8% versus 8.4%; P = 0.001). Coexpression of HER2 with HER4 was associated with reduced recurrence compared with HER2-only positive DCIS (P = 0.003). This association remained significant when analyzing only high nuclear-grade DCIS (P = 0.015). Low nuclear grade, low proliferation rate and presence of HER4 expression were independent predictors of nonrecurrence. Potentially, HER4 expression may identify women who could avoid radiotherapy after breast-conserving surgery for DCIS.
Key Words: HER2 • HER3 • HER4 • Breast cancer • DCIS
This article has been cited by other articles:
|
|
 |
|
  A. Guerrieri-Gonzaga, E. Botteri, N. Rotmensz, F. Bassi, M. Intra, D. Serrano, G. Renne, A. Luini, M. Cazzaniga, A. Goldhirsch, et al. Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years Oncologist, March 1, 2009; 14(3): 201 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Feng, R. S. Muraoka-Cook, D. Hunter, M. A. Sandahl, L. S. Caskey, K. Miyazawa, A. Atfi, and H. S. Earp III The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its Proteolytically Derived Signaling Isoforms for Degradation Mol. Cell. Biol., February 1, 2009; 29(3): 892 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-P. Chuu, R.-Y. Chen, J. L. Barkinge, M. F. Ciaccio, and R. B. Jones Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective Mol. Cancer Res., June 1, 2008; 6(6): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Feng, C. I. Sartor, D. Hunter, H. Zhou, X. Yang, L. S. Caskey, R. Dy, R. S. Muraoka-Cook, and H. S. Earp III The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell Proliferation Mol. Endocrinol., August 1, 2007; 21(8): 1861 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Czerniecki, R. E. Roses, and G. K. Koski Development of Vaccines for High-Risk Ductal Carcinoma In situ of the Breast Cancer Res., July 15, 2007; 67(14): 6531 - 6534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Farnie, R. B. Clarke, K. Spence, N. Pinnock, K. Brennan, N. G. Anderson, and N. J. Bundred Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways J Natl Cancer Inst, April 18, 2007; 99(8): 616 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Czerniecki, G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, et al. Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion Cancer Res., February 15, 2007; 67(4): 1842 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, L. L. Sullivan, S. S. Nair, C. C. Williams, A. K. Pandey, L. Marrero, R. K. Vadlamudi, and F. E. Jones Coregulation of Estrogen Receptor by ERBB4/HER4 Establishes a Growth-Promoting Autocrine Signal in Breast Tumor Cells Cancer Res., August 15, 2006; 66(16): 7991 - 7998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Naresh, W. Long, G. A. Vidal, W. C. Wimley, L. Marrero, C. I. Sartor, S. Tovey, T. G. Cooke, J. M.S. Bartlett, and F. E. Jones The ERBB4/HER4 Intracellular Domain 4ICD Is a BH3-Only Protein Promoting Apoptosis of Breast Cancer Cells. Cancer Res., June 15, 2006; 66(12): 6412 - 6420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Edwards, P. Traynor, A. F. Munro, C. F. Pirret, B. Dunne, and J. M.S. Bartlett The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer Clin. Cancer Res., January 1, 2006; 12(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
